Company Overview - Kestra operates in a significantly underserved market with an urgent need for its clinical solutions [2] - The company has a differentiated and clinically proven product offering [3] - Kestra's total addressable market (TAM) is approximately $10 billion in the U.S., with a larger market size internationally [3] Market Opportunity - Current market penetration is estimated at $1 billion, representing a substantial opportunity for growth as a new entrant [3] - The market previously operated as a monopoly, indicating potential for disruption and scalability for Kestra's business model [4] Product Offering - The first product launched by Kestra is the cardiac recovery platform, which includes the ASSURE Wearable Cardioverter [5] - The company positions itself as a wearable medical device and digital healthcare provider [4] Leadership and Strategy - Kestra boasts a proven leadership team with prior experience in successfully navigating similar market landscapes [4] - The business model is characterized by attractive unit economics, enhancing its scalability potential [4]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月，专注于可穿戴医疗设备和数字医疗的公司Kestra Medical Technologies, Ltd.（以下简 称"Kestra"）宣布，其扩大规模的首次公开募股（IPO）定价为每股 17.00美元 ，共发行 11,882,352 股 普通股。 美国银行证券（BofA Securities）、高盛（Goldman Sachs & Co. LLC）和 Piper Sandler 担任此次 发行的主要簿记管理人。富国银行证券和 Stifel 担任簿记管理人， Wolfe | Nomura Alliance 担任此次 发行的联合管理人。 此前 Kestra Medical 提交了一份S-1表格，确认其计划通过首次公开募股（IPO）上市，并且设定了筹 集约 1亿美元 的目标。 相关阅读： 冲刺IPO！医械独角兽融资超14亿 # A S S U R E W C D 系统 Kestra Medical的旗舰产品ASSURE Wearabl ...